4861-79-4

Usage

Uses

Used in Pharmaceutical Industry:
Magnesium Methyl Carbonate is used as a starting material for the synthesis of various pharmaceutical compounds, specifically oleanane and ursane triterpenoids. These triterpenoids are known for their active inhibition of nitric oxide production in mouse macrophages, which can be beneficial in the development of treatments for inflammatory diseases and conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, Magnesium Methyl Carbonate serves as a versatile reagent for the preparation of a wide range of organic compounds. Its ability to act as a base and a mild antiseptic makes it a valuable component in the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
Magnesium Methyl Carbonate is also utilized in research and development laboratories for the study of its properties and potential applications. Its unique characteristics make it an interesting subject for scientific investigation, which could lead to the discovery of new uses and applications in various industries.

InChI:InChI=1/C10H15NO3/c1-11-6-9(13)7-3-4-8(12)10(5-7)14-2/h3-5,9,11-13H,6H2,1-2H3/t9-/m0/s1

Upstream product

• 67-56-1 methanol 
• 124-38-9 carbon dioxide 
• 109-88-6 magnesium methanolate 
• 7439-95-4 magnesium 

Downstream Products

• 6005-95-4 acide tetrahydro-2-oxo-5-phenylfurane-3-carboxylique 
• 147596-60-9 cis/trans-5-(4-Fluorphenyl)-2-oxo-4,5-dihydro-3H-furan-3-carbonsaeure 
• 149530-23-4 5,5-Bis-(4-fluorphenyl)-2-oxo-4,5-dihydro-3H-furan-3-carbonsaeure 
• 92270-02-5 <3-(13)C>Benzoylessigsaeure 
• 38134-93-9 1.6-Dihydroxy-2-naphthylcarbonsaeure 
• 88843-11-2 (5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-10,13,17-trimethyl-3-oxo-hexadecahydro-cyclopenta[a]phenanthrene-2-carboxylic acid 
• 29285-16-3 3-(4-nitrophenyl)-3-oxopropanoic acid 
• 13422-77-0 3-(4-methoxy-phenyl)-3-oxo-propionic acid 
• 22928-28-5 2,4-dihydroxyisophthalic acid 
• 52244-86-7 3-(4-dodecyloxy-phenyl)-3-oxo-propionic acid methyl ester 
• 52244-81-2 3-(4-hexadecyloxy-phenyl)-3-oxo-propionic acid methyl ester 
• 55017-92-0 methyl 3-[o-(hexadecyloxy)phenyl]-3-oxopropionate 
• 493-46-9 (+)-protolichesterinic acid 
• 18709-01-8 cyclohexanone-2-carboxylic acid 

Relevant academic research and scientific papers

BIOSYNTHESIS OF CANNABINOID PRODRUGS AND THEIR USE AS THERAPEUTIC AGENTS

The present invention provides methods for producing cannabinoid prodrugs. Also described are pharmaceuticals acceptable compositions of the prodrugs and a system for the large-scale production of the prodrugs.

METHODS FOR THE MANUFACTURE OF CANNABINOID PRODRUGS, PHARMACEUTICAL FORMULATIONS AND THEIR USE

Described are methods for producing cannabinoid prodrugs as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents for treating diseases.

BIOENZYMATIC SYNTHESIS OF THC-v, CBV AND CBN AND THEIR USE AS THERAPEUTIC AGENTS

The present invention provides methods for producing cannabinoids. More specifically, the invention is directed to the bio-enzymatic synthesis of THC-v, CBV and CBN by contacting a compound according to Formula I with a cannabinoid synthase enzyme. Also described is a system for producing these pharmaceutically important cannabinoids and the use of such cannabinoids as therapeutic agents.

APPARATUS AND METHODS FOR THE SIMULTANEOUS PRODUCTION OF CANNABINOID COMPOUNDS

The present invention provides an apparatus and methods for simultaneously producing different compounds in various ratios under set conditions.

BIOSYNTHESIS OF CANNABINOIDS

The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.

Synthesis and conformational studies on 3-o-tolylhydantoins by NMR and molecular modeling: Dipole-π attractions in peptides and proteins

5-Pentafluorobenzyl-3-o-tolylhydantoin (2) was synthesized for reducing this π-electron density, and NMR studies have shown that we have succeeded in changing the conformation of 2 into an extended system instead of the folded conformation for the non-fluorinated compound, 5-benzyl-3-o-tolylhydantoin (1). Molecular modeling has also confirmed the extended structure for 2. An approach has been found for possibly modulating the physiological activity of peptides containing aromatic amino acids.